What RevMed’s pancreatic cancer drug meant for one patient

Article excerpt

Revolution Medicines presented data on daraxonrasib, its pancreatic cancer drug, at a major oncology conference, an announcement that drew a standing ovation from doctors. The company's work targets KRAS mutations, a notoriously difficult genetic driver that fuels many pancreatic cancers. STAT's biotech podcast explores what the drug's promise means for patients dealing with one of cancer's deadliest forms, while also examining why biotech stocks tanked this week despite the milestone.